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Abstract
Purpose:  PET  with 68Ga-DOTATOC  allows  for  imaging  and  quantitative  assessment  of  somato-
statin receptor  expression  in  neuroendocrine  tumors  (NET).  The  aim  of  this  retrospective  study
was to  analyze  whether  pre-therapeutic 68Ga-DOTATOC  PET/CT  is  able  to  predict  response  to
Peptide Receptor  Radionuclide  Therapy  (PRRT).
Patients  and  methods:  Forty  patients  with  advanced  stage  NET  were  treated  with  a  ﬁxed  dose
of 90Y-DOTATOC  (5550  or  3700  MBq).  Prior  to  PRRT,  each  patient  received 68Ga-DOTATOC  PET/CT.
Treatment  results  were  evaluated  after  3  months  by  CT,  tumor  marker  levels  and  clinical  course
68 90and correlated  with Ga-DOTATOC  uptake  (SUVmax)  and  the  assumed  uptake  of Y-DOTATOC  in
tumor manifestations  (MBq/g).  ROC  analysis  and  pairwise  comparison  of  area  under  the  curve
(AUC) were  performed  with  pre-treatment  uptake  of 68Ga-DOTATOC,  assumed  uptake  of 90Y-
DOTATOC and  treatment  activity  alone  and  in  relation  to  body  weight  as  continuous  variables,
and response/no  response  as  classiﬁcation  variable.
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Results:  According  to  conventional  criteria  (tumor  shrinkage,  decrease  of  tumor  markers,
improved or  stable  clinical  condition),  20  patients  were  classiﬁed  as  responders,  16  as  non-
responders  and  in  four  patients  ﬁndings  were  equivocal.  Using  a  SUV  more  than  17.9  as  cut-off
for favorable  outcome,  PET  was  able  to  predict  treatment  response  of  all  responders  and  15
out of  16  non-responders.  All  four  patients  with  equivocal  ﬁndings  showed  SUV  less  than  or
equal to  17.9  and  soon  experienced  tumor  progression.  The  assumed  uptake  of 90Y-DOTATOC  in
tumor manifestations  using  a  cut-off  more  than  1.26  MBq/g  as  predictor  of  response  was  able
to correctly  classify  19  out  of  20  responders,  and  14  out  of  16  non-responders.  In  all  patients
with equivocal  ﬁndings,  the  assumed  uptake  of 90Y-DOTATOC  was  below  1.26  MBq/g.
Conclusion:  Pre-therapeutic 68Ga-DOTATOC  tumor  uptake  as  well  as  assumed  uptake  of 90Y-
DOTATOC are  strongly  associated  with  the  results  of  subsequent  PRRT.  The  deﬁned  cut-off  values
should be  conﬁrmed  by  prospective  studies  and  may  then  provide  the  rationale  for  individual
dosing and  selecting  patients  with  high  likelihood  of  favorable  treatment  outcome.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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teuroendocrine  tumors  (NET)  are  relatively  rare  neoplasms,
ainly  originating  from  the  digestive  system.  Usually  they
end  to  be  well  differentiated  and  consecutively  slow  pro-
ressing.  At  the  time  of  diagnosis,  they  are  often  in  an
noperable  or  advanced  stage  with  multiple  lymph  node
nd/or  distant  metastases  [1—7].
Since  therapeutic  options  are  limited  and  cure  rates  are
ow,  localization  and  assessment  of  disease  extent  are  cru-
ial  for  the  clinical  management  of  NET.  Commonly  used
iagnostic  modalities  include  morphological  imaging  pro-
edures  like  ultrasound,  computerized  tomography  (CT),
agnetic  resonance  imaging  (MRI),  and  functional  imag-
ng  techniques,  including  the  use  of  somatostatin  receptor
cintigraphy  with  e.g. 111Indium  DTPA  octreotide  or 99mTc-
DDA/HYNIC-octreotate,  and  positron  emission  tomography
ith 68Ga-somatostatin  analogues.
Treatment  is  multidisciplinary  and  should  be  indi-
idualized  according  to  the  tumor  type,  burden,  and
ymptoms.  Therapeutic  tools  include  surgery,  interventional
adiology  (e.g.  chemoembolisation  and  radiofrequency  abla-
ion),  medical  treatment  such  as  somatostatin  analogues
e.g.  octreotide  or  lanreotide),  interferon  ,  chemother-
py,  radiotherapy  (e.g.  of  symptomatic  spine  lesions)  as
ell  as  targeted  treatments  with  multi-tyrosine  kinase
nhibitors  (e.g.  sunitinib)  or  mTOR  (mammalian  target  of
apamycin)  inhibitors  like  everolimus,  and  peptide  receptor
adionuclide  therapy  (PRRT)  with  radiolabeled  somatostatin
nalogues  [8—11].
NET  are  characterized  by  the  over-expression  of  somato-
tatin  receptors  (SSTR)  on  the  cell  membrane,  thus  enabling
he  therapeutic  use  of  somatostatin  analogues,  which  have
een  shown  to  be  able  to  reduce  signs  and  symptoms  of
ormone  hypersecretion,  improve  quality  of  life,  and  slow
umor  growth.  Although  the  subtypes  and  number  of  SSTR
xpressed  in  neoplastic  cells  can  be  variable,  subtype  2  is
learly  predominant  [12].  Expression  of  these  speciﬁc  recep-
ors  forms  the  molecular  basis  for  the  successful  use  of
adiolabeled  somatostatin  analogues,  both  for  imaging  and
herapy  [13,14].
PRRT  with  radiolabelled  somatostatin  analogues  such  as
0Yttrium-DOTA0-D-Phe1-Tyr3-octreotide  (90Y-DOTATOC)  has
een  explored  in  NET  for  more  than  a  decade  and  is
 promising  treatment  modality  in  the  management  of
r
Patients  with  inoperable  or  metastasized  NET  [15—17].
resent  knowledge  and  clinical  studies  indicate  that  these
adiopharmaceuticals  are  able  to  irradiate  tumors  and  their
etastases  via  internalization  through  SSTR  (mainly  sub-
ype  2).  PRRT  can  deliver  radiation  doses  to  tumors,  which
re  adequate  to  achieve  signiﬁcant  volume  reduction  with
artial  and  complete  objective  responses  in  up  to  30%  of
atients  [18,19].  Side  effects,  involving  kidneys  and  bone
arrow,  are  mild,  if  adequate  renal  protection  is  used  [20].
 consistent  survival  beneﬁt  is  reported  with  morphologic
nd  biochemical  response  to  PRRT  as  well  as  signiﬁcant
mprovement  of  quality  of  normal  daily  life  [21—24].
In  clinical  routine,  morphological  imaging  procedures,
articularly  CT  and  MRI,  are  well  established  for  the  eval-
ation  of  therapy  response.  The  assessment  of  treatment
utcome  for  solid  tumors  is  based  on  the  Response  Evalua-
ion  Criteria  in  Solid  Tumors  (RECIST),  deﬁning  response  as  a
0%  decrease  in  the  largest  diameter  of  the  tumor  [25,26].
NET  are  generally  rather  heterogeneous  in  terms  of
athomorphology,  biologic  behavior,  and  peptide  receptor
xpression,  i.e.  in  some  tumor  areas  a  high  receptor  den-
ity  may  be  found  whereas  other  areas  lack  receptors.
nternal  radiation  therapy  with  high-energy  -emitters  (e.g.
0Y)  induces  damage  to  tumor  cells  during  a  relatively
ong  period  of  time.  Thus,  tumor  shrinkage  may  be  small
r  even  not  detectable  although  tumor  cells  are  replaced
y  necrotic  and  ﬁbrotic  tissue.  The  distribution  of  radia-
ion  dose  throughout  a tumor  depends  on  tumor  size,  the
adionuclide  used  and  its  intratumoral  distribution.  Factors
uch  as  biologic  properties  of  the  tumor,  afﬁnity  of  target-
ng  molecules  to  tumor  cells,  and  extent  and  permeability  of
he  tumor  vasculature  determine  the  distribution  of  target-
ng  molecules  within  the  tumor.  Furthermore,  the  physical
haracteristics  of  the  radionuclides  delivered  by  the  target-
ng  molecules  have  a signiﬁcant  inﬂuence,  particularly  the
nergy  spectrum  of  the  ionizing  particles,  which  determines
he  range  of  the  energy  emission.  Radiosensitivity,  repair
apacity,  proliferation  rate  and  induction  of  apoptosis  after
ow-dose  radiation  are  additional  factors  that  impose  a  fur-
her  level  of  variability  to  the  response  of  tumor  cells  to
adiation  [27—30].
SSTR-based  functional  imaging,  such  as 68Ga-DOTATOC
ET,  allows  for  imaging  and  quantitative  assessment  of
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NPeptide  receptor  radionuclide  therapy  of  neuroendocrine  tu
radioactivity  distribution,  in  particular  binding  to  somato-
statin  receptors  in  tumor  manifestations  as  well  as  in  normal
tissue  [31—33].
The  aim  of  this  retrospective  study  was  to  analyze
whether  response  to  PRRT  is  correlated  to  pre-therapeutic
tumor  uptake  of 68Ga-DOTATOC  and  to  the  assumed  uptake
of 90Y-DOTATOC  within  the  tumor  and  if  so,  whether  cut-off
values  for 68Ga-DOTATOC  uptake  and  assumed 90Y-DOTATOC
uptake  can  be  deﬁned  to  predict  favorable  outcome  of  PRRT.
Materials and methods
Patients
A  total  of  40  consecutive  patients  (23  men,  17  women;  age
30—79  years,  mean  ±  SD:  61.3  ±  11.6)  with  advanced  stage
NET,  treated  between  November  2004  and  November  2008,
were  included  in  this  retrospective  study:  12  patients  with
NET  of  pancreatic  origin,  14  patients  with  NET  of  the  intes-
tine  (small  or  large  bowel),  one  of  bronchial  origin,  nine
patients  with  NET  of  unknown  primary,  one  patient  with
glucagonoma,  one  patient  with  medullary  thyroid  cancer,
one  patient  with  medullary  thymoma  and  one  patient  with
phaeochromocytoma.
In  all  patients,  a  NET  was  histologically  conﬁrmed  as  well
as  progressive  disease  on  the  basis  of  previous  morphological
imaging.  SSTR-expression  was  documented  by 68Ga-DOTATOC
PET  in  all  patients.  In  this  group  of  advanced  tumors,  various
therapeutic  procedures  had  been  performed  prior  to  PRRT.
Seventeen  patients  were  treated  with  surgery  alone,  three
patients  had  received  additional  chemotherapy  and  one
patient  radiofrequency  ablation  of  liver  metastases  after
surgery,  ﬁve  patients  were  so  far  treated  by  chemotherapy
alone,  one  patient  had  surgery,  radiotherapy  of  spine  lesions
and  radiofrequency  ablation  of  liver  metastases,  one  patient
was  treated  with  chemoembolisation  of  liver  metastases,
and  19  patients  received  long-acting  somatostatin  analogues
alone  or  in  combination  with  interferon-. Patient  charac-
teristics,  localization  of  primary  tumors  and  pre-treatment
are  listed  in  Table  1.
This  retrospective  study  was  approved  by  the  local  ethi-
cal  committee  and  written  informed  consent  was  obtained
from  all  patients  before  they  were  enrolled  in  the  study.
PRRT
The  patients  were  hospitalized  for  48  h  in  accordance
with  the  legal  requirements  for  radiation  protection.
A  uniform  application  protocol  with  ﬁxed  radioactivity
doses  was  used.  In  19  patients,  5550  MBq  (5300—6350  MBq,
mean  ±  SD,  5759.4  ±  242.5)  and  in  21  patients,  3700  MBq
(3350—3910  MBq,  mean  ±  SD,  3712  ±  131.3)  were  injected.
Intravenous  infusion  of  2000  mL  of  amino  acid  solution
(Ringer’s  lactated  Hartmann  solution,  Proteinsteril  [B.  Braun
Medical  AG,  Sempach,  Switzerland]  HEPA  8%,  Mg  5-Sulfat
[B.  Braun  Medical  AG,  Sempach,  Switzerland])  to  inhibit
tubular  reabsorption  of  the  radiopeptide  was  started  30  min
before  and  continued  until  3  h  after  treatment  [34,35].
During  the  evaluation  period,  the  radioactivity  dose  was
reduced  from  5550  MBq  (n  =  19)  to  3700  MBq  (n  =  21)  accord-
ing  to  consensus  of  a  joint  workshop  of  the  German  Society  of
m
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uclear  Medicine  and  the  German  Society  of  Endocrinology
n  2006  in  order  to  standardize  therapy  protocols.
8Ga-DOTATOC PET/CT
OTA0-D-Phe1-Tyr3-octreotide  (DOTATOC)  was  provided  by
PT  (Berlin,  Germany). 68Ga-Generators  (TiO2 phase  based)
rom  Cyclotron  Co.  Ltd.,  Russia,  were  used  (1110  or
850  MBq).  HCl  (37%),  water  for  trace  analysis  and  acetone
ere  purchased  from  Fluka  (Germany)  and  of  highest  purity
vailable  (minimum  traces  of  metals). 68Ga-DOTATOC  was
ynthesized  as  described  previously  in  a  home-made  manu-
lly  operable  synthesizing  device  [36].
Each  patient  received  a 68Ga-DOTATOC  PET/CT  scan
efore  (i.e.  1  to  a  maximum  of  3  days)  and  3  months  after
RRT.  Long-acting  somatostatin  analogues  were  discontin-
ed  for  at  least  6  weeks  before  initial  and  follow-up  PET/CT
cans.
PET/CT  imaging  started  20  min  after  administration  of
50—170  MBq  of 68Ga-DOTATOC.  The  examinations  were
erformed  using  the  Hi-Rez  Biograph  16  PET/CT  device
Siemens  Medical  Solutions,  Knoxville,  USA),  consisting  of
 high-resolution  3D  LSO  PET  and  a  state-of-the-art  16-row
ulti-detector  CT  (MDCT).  The  non-enhanced  CT  data  were
sed  for  attenuation  correction  of  PET  emission  images.
ET  images  were  reconstructed  using  an  iterative  algorithm
ordered-subset  expectation  maximization:  2  iterations,  8
ubsets).  To  obtain  diagnostic  CT  data,  in  all  patients  a
ulti-phase  CT  protocol  with  intravenous  administration  of
20  mL  iodinated  contrast  agent  (Ultravist  370,  Schering,
erlin,  Germany)  at  a  ﬂow  of  2—3  mL/s  was  performed.
ssessment of laboratory parameters
hromogranin  A,  neuron-speciﬁc  enolase  (NSE)  and  sero-
onin  were  measured  in  all  patients.  Calcitonin  was
ssessed  only  in  one  patient  (patient  No.  28,  medullary
hyroid  cancer).  NSE  was  measured  by  a  non-competitive
mmunoassay  based  on  time-resolved  ampliﬁed  cryptate
mission  (TRACE)  technology  (Brahms,  Henningsdorf,  Ger-
any).  Chromogranin  A  and  calcitonin  were  determined
sing  an  enzyme-linked  immuno  sorbent  assay  (ELISA;
ako,  Glostrup,  Denmark).  Serotonin  was  measured  by
igh-pressure  liquid  chromatography  (HPLC;  Chromsystems,
unich,  Germany).
ollow-up
ET/CT  images  were  interpreted  by  two  experienced
uclear  medicine  physicians  and  two  experienced  radio-
ogists  in  consensus,  each  having  more  than  10  years
xperience  in  oncological  imaging.  The  interpreters  had
ccess  to  all  clinical  information.
Distribution  of 68Ga-DOTATOC  was  evaluated  visually  and
emi-quantitatively  using  standard  uptake  values  (SUVmax)
ormalized  for  body  weight.  The  criterion  for  malignancy
as  focally  increased  uptake  higher  than  that  of  the  liver.
umber,  uptake  (PET)  and  size  (CT)  of  lesions  were  deter-
ined.  For  each  patient,  a  reference  lesion,  which  was  best
isible,  easy  to  deﬁne  and  more  than  or  equal  to  1.5  cm
n  diameter  was  assigned  for  follow-up  (PET:  comparison  of
re-  and  post-therapeutic  SUVmax).  The  assumed  uptake  of
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Table  1  Patient  characteristics.
No Location  of  primary  NET  PRRT  [MBq] Response 68Ga 90Y Activity/body  weight Pre-treatment
PET  CT  Tumor
marker
Clinical
course
1  Pancreas  5661  (−)  (−)  (−)  (−)  36.6  3.6999  101.09  CTx,  SA
2  Pancreas  5875  (−)  (−)  (−)  (−)  23.8  2.8363  119.17  CTx,  SA
3  Ileocecal  valve  6100  (−)  (−)  (−)  (−)  31.3  2.3284  74.39  OP,  SA
4  Pancreas  3730  (−)  (−)  (−)  (−)  53.3  2.2338  41.91  SA
5  Pancreas  3794  (−)  (−)  (−)  (−)  52.1  2.4711  47.43  CTx
6  Pancreas  3760  (−)  (−)  (−)  (−)  39.6  2.0394  51.5  CE,  SA
7  Pancreas  3730  (−)  (−)  (−)  (−)  29.8  2.0973  45.48  CTx
8  Jejunum  3750  (−)  (−)  (−)  (−)  34.5  2.3522  68.18  OP
9  Pancreas  3760  (−)  (−)  (−)  (−)  36.4  1.9834  54.49  None
10  Ileum  3700  (−)  (−)  (−)  (−)  30.4  0.9098  30.33  None
11  Coecum  5800  (−)  SD  (−)  (−)  25.7  2.4436  95.08  OP
12  Bronchus  5650  (−)  SD  (−)  (−)  33.6  2.8765  85.61  OP,  SA
13  Pancreas  5940  (−)  SD  (−)  (−)  20.3  2.3877  117.62  SA  and  IF
14  Unknown  primary  5300  (−)  SD  (−)  (−)  21.7  1.9168  88.33  None
15  Pancreas  3730  (−)  SD  (−)  (−)  28.7  2.0199  70.38  SA
16  Ileum  3714  (−)  SD  (−)  (−)  31.3  1.6607  53.10  OP,  SA
17  Jejunum  3910  (−)  SD  (−)  (−)  22.5  1.2938  57.50  None
18  Pancreas  3340  (−)  SD  (−)  (−)  35.6  1.303  36.3  None
19  Pancreas  3773  (−)  SD  (−)  (−)  34.9  1.2886  37.36  OP
20  Glucagonoma  6350  (−)  SD  (−)  (−)  20.4  1.9627  96.21  OP
21  Ileum  5481  (+)  SD  (−)  (−)  11.4  1.0414  91.35  OP,  SA
22  Unknown  primary  3670  (+)  SD  (−)  (−)  16  0.9626  60.16  SA
23  Ileocecal  valve  3350  (+)  SD  (−)  SD  3.5  0.1379  39.41  OP,  SA
24  Ileum  3815  (+)  SD  (−)  SD  17.9  0.9618  53.73  OP,  SA
25  Thymus  5683  SD  (+)  (+)  (+)  3.7  0.3286  88.8  OP,  SA
26  Coecum  5855  (+)  (+)  (+)  (+)  15.4  1.4088  91.48  OP
27  Unknown  primary  5416  (+)  (+)  (+)  (+)  26.7  2.2954  85.97  SA
28  Thyroid  (medullary)  5650  (+)  (+)  (+)  (+)  6.7  0.6106  91.13  OP,  CTx
29  Rectum  5900  (+)  (+)  (+)  (+)  13.2  0.9055  68.6  OP
30  Pancreas  5621  (+)  (+)  (+)  (+)  13.4  0.8463  63.16  OP,  RFA,  SA
31  Unknown  primary  3729  (+)  (+)  (+)  (+)  7.1  0.3894  54.84  OP,  CTx
32  Unknown  primary  3757  (+)  (+)  (+)  (+)  5.8  0.3352  57.8  OP,  RFA,  RT  (spine)
33  Unknown  primary  5910  (+)  (+)  (+)  (+)  13.6  1.0438  76.75  OP,  CTx,  SA
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Table  1  (Continued)
No Location  of  primary  NET PRRT  [MBq] Response 68Ga 90Y Activity/body  weight Pre-treatment
PET  CT  Tumor
marker
Clinical
course
34  Unknown  primary 5630  (+)  (+)  (+)  (+)  16.2 1.1123 68.66 None
35  Pheochromocytoma 5870  (+)  (+)  (+)  (+)  9.4 0.726 77.23 OP
36  Ileum  5736  (+)  (+)  (+)  (+)  16.5  1.2619  76.48  OP,  SA
37  Unknown  primary 3755  (+)  (+)  (+)  (+)  11.6  0.6406  55.22  SA
38  Ileocecal  valve 3711  (+)  (+)  (+)  (+)  9.1  0.4966  54.57  OP,  SA
39  Ileum  3726  (+)  (+)  (+)  (+)  7  0.3952  56.46  OP
40  Unknown  primary  3756  (+)  (+)  (+)  (+)  5.7  0.2933  51.45  CTx
PRRT: peptide receptor radionuclide therapy; 68Ga: pre-therapeutic 68Ga-DOTATOC uptake [SUVmax]; 90Y: pre-therapeutic assumed 90Y-DOTATOC uptake [MBq/lesion (g) × SUVmax]; CTx:
chemotherapy; SA: somatostatin analogues; OP: operation; CE: chemoembolization; IF: interferon-; RFA: radiofrequency ablation; RT: radiotherapy; SD: stable disease.
(−): regression: PET (SUVmax decrease of more than 15%); CT (decrease of tumor size or stable disease according to RECIST criteria), tumor marker (decrease of more than 15%); clinical
course (weight gain, improvement of clinical symptoms).
(+): progression: PET (SUVmax increase of more than 15% and/or new lesion(s)); CT (increase of tumor size according to RECIST), tumor marker (increase of more than 15%); clinical
course (weight loss, deterioration of clinical symptoms).
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0Y-DOTATOC  within  the  reference  lesion  was  assessed  by
he  administered  treatment  radioactivity  [MBq]  divided  by
he  body  weight  [g]  and  multiplied  by  the  SUVmax  of 68Ga-
OTATOC  uptake.  Response  Criteria  In  Solid  Tumors  (RECIST)
as  used  for  CT  to  evaluate  tumor  response  to  treatment.
In  all  patients,  plasma  levels  of  chromogranin  A,
euron-speciﬁc  enolase,  and  serotonine  were  measured
re-therapeutically.  For  follow-up,  only  those  tumor  mark-
rs  with  increased  pre-therapeutic  plasma  levels  were
sed.  In  only  one  patient  calcitonin  was  assessed  pre-  and
ost-therapeutically  (patient  No.  28,  medullary  thyroid  can-
er).  For  the  evaluation  of  clinical  course,  we  assessed
he  general  condition,  weight  gain  or  loss,  and  symp-
oms  (e.g.  ﬂush,  diarrhea,  abdominal  discomfort)  pre-  and
ost-treatment.
Treatment  results  were  evaluated  after  3  months  by  CT,
umor  markers  (chromogranin  A,  serotonin,  neuron-speciﬁc
nolase  [NSE],  calcitonin),  and  clinical  course  and  corre-
ated  with  pre-therapeutic 68Ga-DOTATOC  uptake  (SUVmax)
nd  the  assumed  uptake  of 90Y-DOTATOC  (MBq/g)  in  tumor
anifestations.  Tumor  regression  was  deﬁned  as  decrease  of
UVmax  of  more  than  15%  (PET),  decrease  of  tumor  size  or
table  disease  (CT)  according  to  RECIST  criteria,  descent  of
umor  marker  of  more  than  15%  and  improvement  of  clinical
ymptoms  or  weight  gain.  Progression  of  disease  was  deﬁned
s  increase  of  SUVmax  of  more  than  15%  and/or  new  lesion(s)
PET);  increase  of  tumor  size  (CT)  according  to  RECIST  crite-
ia,  rising  tumor  marker  of  more  than  15%,  and  deterioration
f  clinical  state  (weight  loss,  and/or  worsening  of  clinical
ymptoms).
tatistical analysislbeit  a  limited  number  of  cases  per  group,  a ROC
nalysis  was  performed  with  pre-treatment  uptake  of
8Ga-DOTATOC,  estimated 90Y-DOTATOC  uptake,  treatment
adioactivity  and  treatment  radioactivity  to  body  weight
c
u
p
igure 1. Responder to peptide receptor radionuclide therapy (PRRT
he pancreas (PET, CT, and Fusion). Before (a) and after (b) PRRT with 3
ptake (arrows), reduction of tumor size (arrowheads), falling tumor ma
ood treatment response. Pre-therapeutic 68Ga-DOTATOC uptake was 53M.Ö.  Öksüz  et  al.
atio  as  continuous  variables,  and  response/no  response
s  classiﬁcation  variable.  To  ﬁnd  diagnostic  cut-off  values
reatment  response  beyond  doubt,  four  patients  with  equiv-
cal  clinical,  CT  and  laboratory  ﬁndings,  but  increasing
8Ga-DOTATOC  uptake  during  follow-up  were  included  in  the
on-responder  group.
ROC  analysis  was  done  according  to  the  method  proposed
y  Hanley  and  McNeil,  with  calculation  of  Youden-index  and
rea  under  the  curve  (AUC),  including  standard  error  and
igniﬁcance  level,  i.e.  maximum  attainable  discrimination
nd  the  utilization  of  radiological  examinations  [37].  AUC
or  pre-treatment  uptake  of 68Ga-DOTATOC,  estimated 90Y-
OTATOC  uptake,  treatment  radioactivity  and  treatment  to
ody  weight  ratio  was  compared  pairwise.  All  calculations
ere  executed  with  MedCalc®,  Version  11.0.
esults
esponse assessment 3 months after PRRT
ccording  to  conventional  criteria  (tumor  shrinkage,
ecrease  of  tumor  markers,  improving  or  stable  clinical
ondition),  20  patients  were  classiﬁed  as  responders,  16  as
on-responders.  In  four  patients,  follow-up  ﬁndings  were
quivocal,  i.e.  PET  demonstrated  increase  of 68Ga-DOTATOC
ptake,  whereas  CT  and  the  clinical  condition  were  stable,
nd  tumor  markers  were  falling.  There  was  no  relevant  dif-
erence  with  regard  to  pre-treatment  and/or  tumor  burden
n  responders  or  non-responders  (Table  1).
Responders  (example  shown  in  Fig.  1, patient  No.  4)
ncluded  11  patients  with  NET  originating  from  the  pancreas,
ix  from  the  intestine  (two  jejunum,  two  ileum,  one  ileoce-
al  valve,  one  coecum),  one  from  the  bronchus,  one  from
nknown  site,  and  one  glucagonoma.
The  group  of  non-responders  (example  shown  in  Fig.  2,
atient  No.  37)  comprised  seven  patients  with  NET  of
). A 63-year-old man with metastasized neuroendocrine tumor of
730 MBq 90Y-DOTATOC. Post-therapeutic decrease of 68Ga-DOTATOC
rkers and improving general condition with weight gain reﬂecting
.3; pre-therapeutic assumed 90Y-DOTATOC uptake was 2.2 MBq/g.
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Figure 2. Non-responder to PRRT. A 62-year-old woman with metastasized neuroendocrine tumor of unknown origin (PET, CT, and Fusion).
Before (a) and after (b) PRRT with 3755 MBq 90Y-DOTATOC. Post-therapeutic increase of 68Ga-DOTATOC uptake (arrows) and of tumor size
dition
r
2
(
c
r
o
o(arrowheads), rising tumor markers and deterioration of clinical con
pre-therapeutic assumed 90Y-DOTATOC uptake was 0.6 MBq/g.
unknown  origin,  ﬁve  of  the  intestine  (two  ileum,  one  ileo-
coecal  valve,  one  coecum,  and  one  rectum),  one  of  the
pancreas,  one  phaeochromocytoma,  one  medullary  thy-
moma,  and  one  medullary  thyroid  cancer.
One  patient  with  NET  of  unknown  primary  and  three
patients  with  intestinal  NET  (two  ileum,  one  ileocoecal
valve)  revealed  equivocal  ﬁndings.  However,  further  follow-
up  of  these  patients  conﬁrmed  tumor  progression  (CT,  tumor
markers)  with  clinical  deterioration  after  9  months  (patient
No.  24;  Fig.  3),  10  months  (patient  No.  22),  12  months
(patient  No.  21),  and  16  months  (patient  No.  23).  Of  the
c
(
c
Figure 3. Equivocal ﬁndings after PRRT. A 60-year-old woman with met
Before (a) and after (b) PRRT with 3815 MBq 90Y-DOTATOC. Post-thera
(arrows), but morphologically stable disease (arrowheads), falling tum
progression (CT, tumor markers, clinical condition) after 9 months. Pre-the
90Y-DOTATOC uptake was 1.0 MBq/g. with weight loss. Pre-therapeutic 68Ga-DOTATOC uptake was 11.6;
esponders,  only  one  patient  had  a  recurrence  after
4  months  (patient  No.  1).
Of  19  patients  who  were  treated  with  5550  MBq
5300—6350  MBq,  mean  ±  SD,  5759.4  ±  242.5),  eight  were
lassiﬁed  as  responder,  10  as  non-responder,  and  one  patient
evealed  equivocal  ﬁndings.  The  NET  of  this  group  were
f  pancreatic  and  unknown  origin,  both  in  four  patients,
f  intestinal  origin  in  six  patients  (two  ileum,  one  ileo-
oecal  valve,  two  coecum,  one  rectum),  and  ﬁve  other  NET
bronchus,  glucagonoma,  thymus,  thyroid,  phaeochromo-
ytoma).
astasized neuroendocrine tumor of the ileum (PET, CT, and Fusion).
peutic equivocal ﬁndings with increase of 68Ga-DOTATOC uptake
or markers and good general condition. Follow-up showed tumor
rapeutic 68Ga-DOTATOC uptake was 17.9; pre-therapeutic assumed
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PRRT  with  3700  MBq  (3350—3910  MBq,  mean  ±  SD,
712  ±  131.3)  was  performed  in  21  patients.  In  this  group,
e  found  12  responders,  six  non-responders,  and  three
atients  with  equivocal  ﬁndings.  The  tumors  comprised
ancreatic  NET  (n  =  8),  intestinal  NET  (n  =  8;  two  jejunum,
our  ileum,  two  ileocecal  valve),  and  ﬁve  patients  with  NET
f  unknown  origin.
tatistical results
8Ga-DOTATOC  uptake
s  illustrated  in  Fig.  4a  and  b, 68Ga-DOTATOC  PET  with  use  of
n  SUVmax  more  than  17.9  (calculated  Youden-index)  as  cut-
ff  facilitates  separation  of  treatment  responders  (SUVmax
anging  from  20.3  to  53.3,  mean  ±  SD,  32.13  ±  9.12)  from
on-responders  (in  15/16:  SUVmax  3.7  to  16.5,  mean  ±  SD,
1.32  ±  5.59)  with  a  sensitivity  of  100%  and  speciﬁcity  of
5%  (95%  CI  83.2—100  and  75.1—99.9,  respectively).  Only
ne  non-responder  presented  with  SUVmax  more  than  17.9
patient  No.  27,  SUVmax  26.7).  All  patients  with  equivocal
t
(
w
1
igure 4. Pre-therapeutic uptake of 68Ga-DOTATOC with SUVmax mor
esponse. All responders were above this threshold. Fifteen out of 16 non
evealed higher 68Ga-DOTATOC uptake (SUVmax 26.7), sensitivity 100%
UVmax less or equal to 17.9, and follow-up of these patients conﬁrm
eterioration.
igure 5. Assumed tumor uptake of 90Y-DOTATOC (treatment activity 
ere correctly predicted using more than 1.26 MBq/g as cut-off value, on
ut of 16 non-responders were correctly identiﬁed, only two patients pre
7 with 2.29 MBq/g, and patient 26 with 1.41 MBq/g). All patients with e
f these patients conﬁrmed signiﬁcant tumor progression (CT, tumor maM.Ö.  Öksüz  et  al.
ndings  had  SUVmax  less  or  equal  to  17.9  (SUVmax  3.5,  11.4,
6.0,  17.9;  mean  ±  SD,  12.2  ±  6.41).
ssumed  tumor  uptake  of 90Y-DOTATOC
s  surrogate  of  the  achieved  target  dose,  the  assumed
umor  uptake  of 90Y-DOTATOC  (Fig.  5a  and  b)  was  cal-
ulated  as  treatment  radioactivity  [MBq]/body  weight
g]  ×  SUVmax.  By  calculating  a  threshold  of  more  than
.26  MBq/g  (Youden-index)  for  positive  therapy  response,
9  out  of  20  responders  could  be  correctly  identiﬁed  (1.28
o  3.69  MBq/g,  mean  ±  SD,  2.17  ±  0.59).  Only  one  patient
evealed  a lower  tumor  uptake  with  0.91  MBq/g  (patient
0).  Of  the  non-responders,  14  out  of  16  were  correctly
lassiﬁed  (0.29  to  1.26  MBq/g,  mean  ±  SD,  0.67  ±  0.32),  only
wo  patients  showed  higher  tumor  uptake  with  2.29  MBq/g
patient  27)  and  1.41  MBq/g  (patient  26).  All  patients
ith  equivocal  ﬁndings  were  below  1.26  MBq/g  (0.13  to
.04  MBq/g,  mean  ±  SD,  0.78  ±  0.43).
e than 17.9 as cut-off value (calculated Youden-index) for therapy
-responders showed an SUV less than 17.9, only one non-responder
 and speciﬁcity 95%. Patients with equivocal ﬁndings revealed an
ed signiﬁcant tumor progression (CT, tumor markers) and clinical
[MBq]/body weight [g] × SUVmax). Nineteen out of 20 responders
ly one patient revealed lower tumor uptake (0.9 MBq/g). Fourteen
sented with higher assumed tumor uptake of 90Y-DOTATOC (patient
quivocal ﬁndings were below the limit of 1.5 MBq/g, and follow-up
rkers) and clinical deterioration.
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Treatment  radioactivity
The  applied  treatment  radioactivity  [MBq]  alone  (Fig.  6a  and
b)  or  in  relation  to  body  weight  [MBq]/[kg]  (Fig.  7a  and
b)  without  considering  speciﬁc  tumor  uptake  measured  by
68Ga-DOTATOC  PET/CT  did  not  reveal  any  correlation  to  ther-
apy  response.  Consequently,  pairwise  comparison  of  AUC
revealed  signiﬁcant  differences  (P  <  0.001)  between  applied
treatment  radioactivity  and 68Ga-DOTATOC  uptake  as  well  as
assumed  tumor  uptake  of 90Y-DOTATOC.  No  signiﬁcant  differ-
ence  was  found  between  AUC  of 68Ga-DOTATOC  uptake  and
assumed  tumor  uptake  of 90Y-DOTATOC.
Discussion
For  clinical  management,  somatostatin  receptor  based
functional  imaging  has  become  standard  for  staging  and
restaging.  It  allows  sensitive  localization  of  tumor  man-
ifestations  and  selection  of  patients  eligible  for  peptide
receptor  radionuclide  therapy  [38,39].
Because  NET  are  generally  slow  progressing,  they  are
often  diagnosed  in  highly  advanced  or  even  inoperable
i
T
p
r
Figure 6. The applied treatment radioactivity alone without consider
not reveal any correlation with therapy response.
Figure 7. The applied treatment radioactivity in relation to body wei
DOTATOC PET/CT did not reveal any correlation with therapy response. with 90Y-DOTATOC  297
tage.  In  this  situation,  treatment  options  are  limited.  Tri-
ls  with  long-acting  somatostatin  analogues,  interferon-,
r  chemotherapy  have  shown  low  response  rates  with  regard
o  cytoreduction  [23,40].
In  the  past  few  years,  treatment  studies  with
omatostatin-based  radioligands  like 90Y-DOTATOC  have
een  conducted  with  encouraging  overall  results,  although
eported  percentages  of  tumor  remission  after  PRRT
ary  considerably  [13,41,42]. The  overall  response  rates
f  our  study  are  comparable  to  those  reported  in  the
iterature.  Possible  reasons  for  this  variation  of  therapy
utcome  include  different  administered  doses  and  dosage
chemes,  e.g.  some  studies  use  dose-escalating  schemes,
hereas  others  use  ﬁxed  doses.  On  the  other  hand,  tumor
haracteristics  (e.g.  the  uptake  on  pre-therapeutic  func-
ional  imaging  with  somatostatin  analogues,  the  estimated
otal  tumor  burden,  or  extent  of  liver  involvement)  may
trongly  inﬂuence  treatment  outcome.  Besides,  differences
n  patient  selection  may  also  play  an  important  role.
herefore,  standardization  of  patient  selection,  therapy
rotocols  and  adequate  methods  for  assessing  therapy
esponse  are  required  [43].
ing speciﬁc tumor uptake measured by 68Ga-DOTATOC PET/CT did
ght without considering speciﬁc tumor uptake measured by 68Ga-
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The  primary  objective  of  our  study  was  to  analyze  retro-
pectively  whether  pre-therapeutic 68Ga-DOTATOC  PET/CT
ight  be  useful  to  identify  patients  with  high  likelihood  to
espond  to  PRRT  with  ﬁxed  doses  of 90Y-DOTATOC.  There-
ore,  we  compared  the  pre-therapeutic  PET/CT  studies  of
ll  patients  scheduled  for  PRRT  with  the  follow-up  examina-
ion  3  months  after  therapy.  In  addition,  we  evaluated  the
linical  assessment  and  laboratory  ﬁndings,  in  particular  the
umor  markers  chromogranin  A,  NSE,  serotonin.
Our  study  demonstrated  that  both  pre-therapeutic 68Ga-
OTATOC  tumor  uptake  as  well  as  assumed  uptake  of
0Y-DOTATOC  are  strongly  associated  with  the  results  of  sub-
equent  PRRT.  Furthermore,  we  could  show  that  prediction
f  therapy  response  might  be  achieved  using  cut-off  values
or 68Ga-DOTATOC  uptake  or  assumed 90Y-DOTATOC  uptake,
.e.  SUVmax  more  than  17.9  or  more  than  1.26  MBq/g,
espectively.
By  using  pre-therapeutic 68Ga-DOTATOC  uptake  with
UVmax  more  than  17.9  as  cut-off  value,  all  respon-
ers  (20/20)  could  be  separated  from  the  majority  of
on-responders  (15/16);  only  one  non-responder  showed  a
igher  tumor  uptake  (SUVmax  26.7).  Four  patients,  who
resented  equivocal  follow-up  ﬁndings,  i.e.  increase  of 68Ga-
OTATOC  uptake,  but  stable  disease  in  morphology  (CT)  and
linical  ﬁndings,  and  falling  tumor  markers  revealed  a  pre-
herapeutic  uptake  SUVmax  less  or  equal  to  17.9.
By  deﬁning  a  threshold  of  more  than  1.26  MBq/g,
he  assumed  pre-therapeutic  tumor  uptake  of 90Y-
OTATOC  (applied  treatment  activity  [MBq]/body  weight
g]  ×  SUVmax),  representing  a  surrogate  of  the  target  dose,
orrectly  identiﬁed  19  out  of  20  responders.  Only  one
esponder  revealed  a  lower  tumor  uptake  (0.91  MBq/g).  The
ajority  of  non-responders  (14/16)  was  correctly  classiﬁed
oo.  Only  two  patients  showed  higher  tumor  uptake  with
.29  MBq/g  and  1.41  MBq/g,  respectively.  Again  the  same
our  patients  with  equivocal  ﬁndings  in  the  follow-up  period
emonstrated  pre-therapeutically  an  assumed 90Y-DOTATOC
umor  uptake  well  below  the  limit  of  1.26  MBq/g.
Our  results  support  previous  data  that  quantitative  anal-
sis  of  pre-  and  post-therapeutic 68Ga-DOTATOC  PET  with
n  increased  SUV  at  baseline  is  associated  with  increased
eceptor  binding,  indicating  a  favorable  therapeutic  effect
44].
Interestingly,  our  data  are  in  contrast  to  a  recently  pub-
ished  paper  by  Gabriel  et  al.  [45]  who  stated  that  SUV
nalysis  did  not  show  a  clear  cut-off  trend,  and  that  there
as  no  signiﬁcant  correlation  with  therapy  outcome  param-
ters.
Several  possible  explanations  for  this  discrepancy  may  be
rged.  First  of  all,  our  patients  received  a  single  PRRT  with
tandardized  doses  in  contrast  to  an  individualized  therapy
rotocol  with  a  variable  number  of  treatment  cycles.  In  our
eries,  PRRT  was  the  only  treatment  modality  that  was  car-
ied  out  between  initial  and  follow-up  examinations  with  the
xception  of  somatostatin  analogues,  which  were  stopped
 weeks  before  the  initial  and  follow-up  evaluation.  Further-
ore,  there  was  only  a  little  time  gap  of  1  day  to  3  days
etween 68Ga-DOTATOC  PET/CT  and  somatostatin  receptor
adiotherapy  to  ensure  maximum  validity  of  uptake  results.
According  to  our  protocol,  distribution  of 68Ga-DOTATOC
as  evaluated  visually  and  semi-quantitatively.  For  quan-
itative  analysis,  one  reference  lesion  was  deﬁned  and
P
(
(M.Ö.  Öksüz  et  al.
ssigned  as  target  lesion  for  follow-up,  both  SUV  analysis
nd  morphological  evaluation.
Another  important  aspect  may  be  the  different  uptake
imes  for 68Ga-DOTATOC.  We  prefer  an  interval  of  20  min
fter  injection  whereas  Gabriel  et  al.  reported  an  acqui-
ition  time  between  90—100  min.  In  our  experience,  an
ptake  time  of 68Ga-DOTATOC  of  20  min  is  adequate  to  obtain
atisfactory  images  with  signiﬁcantly  less  disturbing  bowel
ctivity,  thus  saving  examination  time,  improving  patient
omfort,  and  optimizing  image  interpretation  [46].
There  are  also  some  limitations  of  this  study.  The  SUV
riteria  were  described  for  imaging  with 18F-FDG,  but  not
or  somatostatin  analogues.  A  decrease  in  SUVmax  can  be
ue  to  tumor  regression,  but  also  due  to  tumor  dedifferen-
iation  with  loss  of  somatostatin  receptors.  Therefore,  the
se  of  this  functional  criterion  should  be  considered  as  a
‘hypothesis’’  until  more  studies  are  available  supporting
his  approach  [47].
A  further  potential  drawback  of  our  study  is  the  missing
ystematic  correlation  with 18F-FDG-PET.  The  heterogeneous
ature  of  NET  makes  it  challenging  to  ﬁnd  a  uniformly  appli-
able  imaging  procedure.  It  is  well  known  that  the  changes  in
he  FDG  uptake  correlate  signiﬁcantly  with  tumor  response
48]. The  main  use  of  FDG  PET  in  diagnosis  of  NET  depends  on
he  grade  of  differentiation  and/or  aggressiveness  of  NETs.
hus, 18F-FDG-PET/CT  could  be  helpful  in  predicting  ther-
py  outcome,  i.e.  patients  with  high 18F-FDG  uptake  are  less
ikely  to  respond  to  PRRT  [49].
The  tumor  uptake,  in  fact,  is  a  rough  estimate  of  the
ubsequent  absorbed  dose  delivered  by  the  PRRT.  Clearly
he  assumed 90Y-DOTATOC  tumor  uptake  constitutes  a  virtual
alue  because 68Ga-DOTATOC  SUVmax  is  not  directly  related
o 90Y-DOTATOC  uptake,  given  the  differences  in  chemistry,
inetics  and,  ultimately,  different  receptor  binding  charac-
eristics  of  the  two  compounds.  Furthermore,  the  variable
mount  of  peptides  used  may  inﬂuence  somatostatin  recep-
or  binding  as  well.  Besides,  tumor  uptake  may  change  over
ime,  depending  on  the  tissue  type.  Hence,  the  transla-
ion  of 68Ga-DOTATOC  uptake  into  an  estimated 90Y-DOTATOC
ptake  is  still  only  a  hypothesis.  Therefore,  a  thorough  dosi-
etric  study,  taking  into  consideration  the  absorbed  dose
f  the  tumor  deriving  from 90Y-DOTATOC  may  have  rendered
his  study  more  accurate.  Another  interesting  issue  would
e  an  analysis  of  the  correlation  of  the  tumor  uptake  with
urvival  parameters  such  as  progression-free  survival,  which
hould  be  evaluated  in  future  studies.
On  the  other  hand, 68Ga-DOTATOC  uptake  is  based  on
ET  technology  which  is  signiﬁcantly  more  reliable  than
ny  other  measurement  techniques  of  planar  scintigraphy
r  SPECT.  However,  we  believe  that 68Ga-DOTATOC  uptake
ay  reﬂect  the  true  therapy  uptake  to  a  certain  extent  and,
herewith,  it  may  be  useful  for  the  purpose  of  optimizing
herapeutic  options  (e.g.  individual  dosing),  and  select-
ng  patients  with  high  probability  of  advantageous  therapy
esults.
onclusionre-therapeutic 68Ga-DOTATOC  tumor  uptake
SUVmax  >  17.9)  as  well  as  assumed  uptake  of 90Y-DOTATOC
>  1.26  MBq/g)  are  strongly  associated  with  the  results  of
mors
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[Peptide  receptor  radionuclide  therapy  of  neuroendocrine  tu
subsequent  PRRT.  The  deﬁned  cut-off  values  should  be
conﬁrmed  by  prospective  studies  and  may  then  provide  the
rationale  for  individual  dosing  and  selecting  patients  with
high  likelihood  of  favorable  treatment  outcome.
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